Real-World Treatment Patterns Have Drastically Changed Over the Past 5 Years

2021 Year in Review - Renal-Cell Carcinoma - Renal-Cell Carcinoma

The treatment landscape for advanced renal-cell carcinoma (RCC) has evolved rapidly in recent years with the approval of new therapeutic options. However, few studies have evaluated real-world treatment patterns and sequencing.1

In a present real-world study, researchers evaluated records for adults diagnosed with advanced RCC between December 2015 and May 2020 from the Flatiron electronic medical record database. Enrolled patients had ≥1 months of medical data following diagnosis of advanced RCC. Baseline clinical and patient characteristics and treatments were evaluated for the entire study period as well as in the period following the approval of dual immune checkpoint inhibition in the United States (April 2018-May 2020).1

A total of 3524 patients with metastatic RCC were enrolled, among whom most were male (68.5%) and had clear-cell disease (68.2%). The median age at diagnosis was 68 years, and 75.8% of patients had intermediate- or poor-risk RCC. Median follow-up from date of diagnosis was 328 days.1

Systemic therapy was initiated in 79.1% of patients. In the whole study period, the most common first-line treatments were monotherapy with a tyrosine kinase inhibitor (TKI; 56.4%), dual checkpoint inhibition (19.1%), combination therapy with a TKI and immune checkpoint inhibitor (9.5%), monotherapy with a checkpoint inhibitor (6.9%), and other therapy (8.1%). Among patients treated after April 2018, the most common first-line treatments were dual immune checkpoint inhibition (36.9%) and TKI monotherapy (32.7%).1

A total of 1303 patients received second-line therapy during the study. In the full study period, the most common treatment sequence was TKI monotherapy to checkpoint inhibitor monotherapy (40.1%). In the post–April 2018 period, fewer patients received TKI monotherapy to checkpoint inhibitor monotherapy (22.8%) and more patients received dual immune checkpoint inhibition followed by TKI monotherapy (21.8%).1

The study investigators concluded that the approval of immunotherapeutics for advanced RCC in the first-line setting changed real-world treatment patterns for advanced RCC.1

Reference

  1. George S, Faccone J, Huo S, et al. Real-world treatment patterns and sequencing for metastatic renal cell carcinoma (mRCC): results from the Flatiron database. J Clin Oncol. 2021;39(6_suppl):Abstract 286.
Related Items
Reduced Starting Dose of Tyrosine Kinase Inhibitors in Patients with Metastatic Renal-Cell Carcinoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Renal-Cell Carcinoma, Dose Escalation/Reduction
Minimal Activity with Sapanisertib in Refractory Renal-Cell Carcinoma
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Active Therapy Improves Survival versus BSC After Disease Progression on Nivolumab and Cabozantinib
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Functional Imaging Predicts Outcomes in Patients Treated with Antiangiogenic Therapy
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Development of a Prognostic Biomarker Score for Nivolumab in Relapsed/Refractory Disease
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Clinical Activity of Lenvatinib with or without Everolimus in Heavily Pretreated Disease
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Nivolumab Rechallenge Associated with Moderate Efficacy
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Stereotactic Radiotherapy Delays Treatment Switch in Those with Oligoprogression
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Study 218: Higher Lenvatinib Starting Dose Trended Toward Better Outcomes
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
BREAKPOINT: Cabozantinib Efficacious After Treatment with First-Line Immunotherapy
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: